Pfizer Pre-Tax Income 2010-2024 | PFE
Pfizer annual/quarterly pre-tax income history and growth rate from 2010 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
- Pfizer pre-tax income for the quarter ending December 31, 2024 was $-0.010B, a 99.76% decline year-over-year.
- Pfizer pre-tax income for the twelve months ending December 31, 2024 was $8.023B, a 658.32% increase year-over-year.
- Pfizer annual pre-tax income for 2024 was $8.023B, a 658.32% increase from 2023.
- Pfizer annual pre-tax income for 2023 was $1.058B, a 96.95% decline from 2022.
- Pfizer annual pre-tax income for 2022 was $34.729B, a 42.85% increase from 2021.
Pfizer Annual Pre-Tax Income
(Millions of US $) |
| 2024 |
$8,023 |
| 2023 |
$1,058 |
| 2022 |
$34,729 |
| 2021 |
$24,311 |
| 2020 |
$7,036 |
| 2019 |
$11,321 |
| 2018 |
$3,594 |
| 2017 |
$12,305 |
| 2016 |
$8,351 |
| 2015 |
$8,965 |
| 2014 |
$12,240 |
| 2013 |
$15,716 |
| 2012 |
$11,242 |
| 2011 |
$11,481 |
| 2010 |
$9,471 |
| 2009 |
$10,674 |
Pfizer Quarterly Pre-Tax Income
(Millions of US $) |
| 2024-12-31 |
$-10 |
| 2024-09-30 |
$4,715 |
| 2024-06-30 |
$-103 |
| 2024-03-31 |
$3,421 |
| 2023-12-31 |
$-4,129 |
| 2023-09-30 |
$-3,352 |
| 2023-06-30 |
$2,269 |
| 2023-03-31 |
$6,270 |
| 2022-12-31 |
$5,231 |
| 2022-09-30 |
$9,001 |
| 2022-06-30 |
$11,447 |
| 2022-03-31 |
$9,050 |
| 2021-12-31 |
$3,827 |
| 2021-09-30 |
$7,843 |
| 2021-06-30 |
$6,949 |
| 2021-03-31 |
$5,692 |
| 2020-12-31 |
$598 |
| 2020-09-30 |
$570 |
| 2020-06-30 |
$3,026 |
| 2020-03-31 |
$2,842 |
| 2019-12-31 |
$-7,870 |
| 2019-09-30 |
$10,727 |
| 2019-06-30 |
$4,141 |
| 2019-03-31 |
$4,323 |
| 2018-12-31 |
$-9,237 |
| 2018-09-30 |
$4,177 |
| 2018-06-30 |
$4,527 |
| 2018-03-31 |
$4,127 |
| 2017-12-31 |
$954 |
| 2017-09-30 |
$3,585 |
| 2017-06-30 |
$3,815 |
| 2017-03-31 |
$3,951 |
| 2016-12-31 |
$776 |
| 2016-09-30 |
$1,604 |
| 2016-06-30 |
$2,410 |
| 2016-03-31 |
$3,561 |
| 2015-12-31 |
$-353 |
| 2015-09-30 |
$2,697 |
| 2015-06-30 |
$3,539 |
| 2015-03-31 |
$3,082 |
| 2014-12-31 |
$1,803 |
| 2014-09-30 |
$3,587 |
| 2014-06-30 |
$4,003 |
| 2014-03-31 |
$2,847 |
| 2013-12-31 |
$3,061 |
| 2013-09-30 |
$3,573 |
| 2013-06-30 |
$5,357 |
| 2013-03-31 |
$3,725 |
| 2012-12-31 |
$1,821 |
| 2012-09-30 |
$2,806 |
| 2012-06-30 |
$4,180 |
| 2012-03-31 |
$2,435 |
| 2011-12-31 |
$1,224 |
| 2011-09-30 |
$3,541 |
| 2011-06-30 |
$3,598 |
| 2011-03-31 |
$3,118 |
| 2010-12-31 |
$982 |
| 2010-09-30 |
$1,414 |
| 2010-06-30 |
$3,926 |
| 2010-03-31 |
$3,149 |
| 2009-12-31 |
$-149 |
| 2009-09-30 |
$3,971 |
| 2009-06-30 |
$3,049 |
| 2009-03-31 |
$3,803 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$143.715B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
